EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Scorecard

How should clinics compare GLP-1 pharmacy quotes?

Dose Diligence research deskSection 09 · Page 9 of 15Last updated 17 Nov 2026

Separate clinical scenarios, payment streams and time periods before comparing prices. The cheapest advertised fill is not necessarily the least expensive complete arrangement.

Require each quotation to disclose:

  • Exact product, presentation, strength, pack size and intended supply duration.
  • Introductory, continuing and conditional prices.
  • Eligibility, refill timing and programme-expiry conditions.
  • Dispensing, shipping, supplies, platform and implementation fees.
  • Responsibility for failed delivery, temperature concerns, replacement and refunds.
  • Minimum quantities, deposits, credit terms and unused commitments.
  • Who pays each charge and which party can negotiate it.
  • Quote expiry and the mechanism for later price changes.

What do current branded-access terms illustrate?

Public prices are conditional patient-access terms, not automatic wholesale benchmarks. NovoCare’s provider page currently describes a two-fill introductory Wegovy injection offer for eligible new participants through December 31, 2026, followed by different continuing prices; it also reserves programme-change rights. Lilly’s Zepbound page distinguishes presentation and dose, defines a month for the cited KwikPen offer as 28 days, and links certain savings to refill timing. Archive the exact applicable terms rather than carrying the headline price through the whole model. (novocare.com)

For a 52-week model, 13 four-week fills are not the same as 12 calendar-month charges. Model actual expected fill dates and pack durations; do not prescribe a treatment schedule through the calculator.

For eligible compounded preparations, test whether the proposed usable quantity survives the applicable dating and in-use limits. FDA’s current GLP-1 communication recommends discarding compounded multi-dose vials within 28 days after first use even where a compounder gives longer instructions. Do not count residual medicine as usable savings without clinical and pharmacy review. (fda.gov)

What is the right cost denominator?

Use both enrolled and successfully fulfilled patient-months. Avoid calling fulfilment clinical success.

For this scorecard:

  • Enrolled patient-month: one patient included in the defined access cohort for the calendar month, with partial-month treatment specified in advance.
  • Successfully fulfilled patient-month: an enrolled patient-month for which all supply due under the agreed plan arrived within the approved windows, with no unresolved supply-quality exception at the measurement cutoff.

This does not establish adherence, clinical benefit or suitability of treatment.

Maintain separate ledgers for:

  1. Clinic expenditure: clinic-paid medicines, service fees, implementation, handling, replacements and wastage, net of realised credits.
  2. Patient expenditure: medicine and access charges actually borne by patients, separately from clinic care fees.
  3. Insurer expenditure: include only where reliable data are available; otherwise mark unknown.

Clinic cost per enrolled patient-month = attributable clinic cost ÷ enrolled patient-months

Clinic cost per successfully fulfilled patient-month = attributable clinic cost ÷ successfully fulfilled patient-months

Keep costs of failed orders in the numerator. For multi-period prepaid packs, show both cash timing and the declared period-allocation method. Avoid double counting a medicine acquisition cost and the payment that merely reimburses it.

What does a worked comparison look like?

The following figures are invented solely to demonstrate the method; they are not supplier prices or observed performance. Assume the same 1,000-patient cohort and clinically matched supply scenario for one calendar month. Patients pay the pharmacy directly for medicine.

Illustrative itemPlan APlan B
Enrolled patient-months1,0001,000
Successfully fulfilled patient-months900970
Clinic platform/service fees$4,000$5,000
Clinic exception-handling cost$2,000$600
Other clinic-paid replacement/administration costs, net$2,000$400
Total attributable clinic cost$8,000$6,000
Clinic cost per enrolled patient-month$8.00$6.00
Clinic cost per successfully fulfilled patient-month$8.89$6.19
Assumed patient medicine charge per matched completed fill$360$380

Handling assumptions are 200 exceptions × 20 minutes × $30/hour for Plan A, and 80 × 15 minutes × $30/hour for Plan B.

Interpretation: Plan B costs the clinic less in this scenario, while Plan A has the lower assumed patient medicine price. Neither fact alone determines the preferred arrangement. The committee must evaluate both affordability and service, and cannot describe a patient medicine-price reduction as clinic margin improvement.

Stress-test at least loss of promotional eligibility, lower volume, an adverse prescribed presentation mix, higher exception rates and a service interruption. Treat these as scenarios, not forecasts.

Explore the table row by row

A working view of the research

Enrolled patient-months

Plan A
1,000
Plan B
1,000

Sources cited on this page

  1. novocare.com · Source 1 ↗https://www.novocare.com/hcp/delivery.html
  2. fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss?be78ca04_page=4&24dc8be8_page=2&2485ce93_page=2&315591c6_page=2
Section sources →